Review ArticlesMaintenance Therapy in Metastatic Solid Tumors Innovative Strategy or Simple Second-line Treatment?Rowinski, Elise MD*; Fournel, Pierre MD*; Bernichon, Emilie MD*; Bouleftour, Wafa PhD*; Magné, Nicolas MD, PhD†; Mery, Benoîte MD* Author Information Departments of *Medical Oncology †Radiotherapy, Lucien Neuwirth Cancer Institute, St Priest en Jarez, France The authors declare no conflicts of interest. Reprints: Elise Rowinski, MD, Department of Medical Oncology, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France. E-mail: [email protected]. American Journal of Clinical Oncology: August 2019 - Volume 42 - Issue 8 - p 615-623 doi: 10.1097/COC.0000000000000574 Buy Metrics Abstract Managing metastatic diseases involves defining the best strategy that is supposed to take into account both efficacy and quality of life. To this end, clinicians use stop and go or maintenance strategies. As a matter of fact, 2 maintenance strategies can be distinguished: continuation maintenance using a drug already present in induction treatment and switch maintenance with a newly introduced drug. Several drugs have been approved as maintenance therapy with several current indications in solid tumors. Questions remain concerning such strategies, notably duration, cost, tolerability, and shortcut between switch maintenance and early second line. If the concept of maintenance strategy remains trendy with numerous trials ongoing, several issues are still pending. The aims of this review were to accurately define and describe the various facets of maintenance therapy through its several indications in real life and then to discuss the future challenges of maintenance therapy in oncology. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.